LP
CATX icon

LMR Partners’s Perspective Therapeutics CATX Stock Holding History

LMR Partners’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-30,000
Closed -$401K – 1251
2024
Q3 		$401K Buy
+30,000
New +$399K ﹤0.01% 870
2024
Q2 		– Sell
-11,549
Closed -$137K – 1123
2024
Q1 		$137K Buy
+11,549
New +$98.5K ﹤0.01% 898

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

LMR Partners's CATX Position: Q4 2024 in Review

LMR Partners sold out of Perspective Therapeutics (CATX) in Q4 2024, closing a stake of 30,000 shares — an estimated $401K sold.

LMR Partners first reported a position in CATX in Q1 2024 and held it in 2 quarters. The position peaked at $401K in Q3 2024. 135 funds tracked by Wall St. Rank hold CATX as of Q4 2024.

  • LMR Partners reported no remaining Perspective Therapeutics position as of Q4 2024 after selling out during the quarter.
  • LMR Partners sold 30,000 Perspective Therapeutics shares in Q4 2024, an estimated $401K.
  • LMR Partners first reported a position in Perspective Therapeutics in Q1 2024 and held it in 2 quarters.
  • LMR Partners's Perspective Therapeutics position peaked at $401K in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2024.

Based on LMR Partners's 13F filing for Q4 2024, filed 14 Feb 2025.